MyFinsight
Home
Blog
About
Proceeds from sales and
maturities of marketable...
$42,801K
(-73.20%↓ Y/Y)
Proceeds from the
issuance of common stock...
$2,630K
Proceeds from the
purchase of common stock...
$219K
(-49.54%↓ Y/Y)
Proceeds from the
exercise of stock options
$57K
(-64.60%↓ Y/Y)
Net cash provided by
investing activities
$15,391K
(-64.32%↓ Y/Y)
Net cash provided by
financing activities
$2,906K
(388.40%↑ Y/Y)
Canceled cashflow
$27,410K
Net decrease in
cash, cash...
-$7,545K
(72.49%↑ Y/Y)
Canceled cashflow
$18,297K
Stock-based compensation
expense
$2,433K
(-68.83%↓ Y/Y)
Non-cash lease expense
$1,304K
(-45.12%↓ Y/Y)
Accrued expenses
$979K
(145.62%↑ Y/Y)
Depreciation
$908K
(-56.33%↓ Y/Y)
Loss on disposal of
fixed assets
-$105K
(-32.91%↓ Y/Y)
Purchases of marketable
securities
$27,410K
(-76.12%↓ Y/Y)
Net cash used in
operating activities
-$25,842K
(63.68%↑ Y/Y)
Canceled cashflow
$5,729K
Net loss
-$24,473K
(62.00%↑ Y/Y)
Operating lease
liabilities
-$1,999K
(43.24%↑ Y/Y)
Prepaid expenses and
other current assets
$1,868K
(2.30%↑ Y/Y)
Accounts receivable
$1,438K
(745.88%↑ Y/Y)
Accounts payable
-$1,109K
(49.41%↑ Y/Y)
Amortization of premiums and
discounts on marketable...
$248K
(-86.14%↓ Y/Y)
Other non-current
assets
$214K
Deferred revenue
-$151K
(97.92%↑ Y/Y)
Related party
collaboration receivable
$71K
(-59.43%↓ Y/Y)
Back
Back
Cash Flow
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)
source: myfinsight.com